subscribe: Posts | Comments

Combining drugs could hold off advanced breast cancer

0 comments

Summary of story from the LA Times, December 7, 2011

Treatment for advanced breast cancer could improve significantly if doctors give women combinations of medications that attack tumors in different ways, two large clinical trials suggest.

In one study, researchers found patients fared better when a breast cancer drug called an aromatase inhibitor was combined with another medication, Afinitor, which is used to treat kidney cancer but is not yet approved for breast cancer.

In the second study, two standard medications for women with a type of breast cancer known as HER2-positive were more effective when the investigational drug pertuzumab was added to the regimen.

The findings, reported on Wednesday at the annual San Antonio Breast Cancer Symposium, point to a new paradigm in treating advanced breast cancer, a field that has not seen significant progress in recent years, cancer specialists said.

The studies signal that advanced breast cancer may be best treated with a strategic combination of targeted medications that wage war on the cancer along several biological pathways.

“These are two terrific, new options. They are laying out a map on the way forward for breast cancer,” said Dr. José Baselga, a professor of medication at Harvard Medical School who was involved in both trials.

“The way forward is by doing smart combination therapies.”

Neither of the regimens in the studies represent a cure, but they could buy more time for patients who are running out of options, oncologists said.

Leave a Reply

Your email address will not be published. Required fields are marked *